Ray Dalio Exact Sciences Corp Transaction History

Bridgewater Associates, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$56.27 - $73.77 $153,054 - $200,654	-2,720 Reduced 32.65%	5,611 $387,000
Q4 2023 Feb 14, 2024	BUY	$59.06 - $75.72 $5,138 - $6,587	87 Added 1.06%	8,331 $616,000
Q3 2023 Nov 13, 2023	BUY	$65.94 - $99.04 $67,918 - $102,011	1,030 Added 14.28%	8,244 $562,000
Q2 2023 Aug 11, 2023	BUY	$62.68 - $95.05 $72,270 - $109,592	1,153 Added 19.02%	7,214 $677,000
Q1 2023 May 12, 2023	BUY	$47.19 - $70.77 $83,856 - $125,758	1,777 Added 41.48%	6,061 $410,000
Q4 2022 Feb 13, 2023	BUY	$30.35 - $53.15 $130,019 - $227,694	4,284 New	4,284 $212,000
Q2 2022 Aug 11, 2022	SELL	$35.61 - $76.23 $343,529 - $735,390	-9,647 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$57.56 - $82.54 $555,281 - $796,263	9,647 New	9,647 $675,000
Q4 2021 Feb 14, 2022	SELL	$72.5 - $100.68 $222,212 - $308,584	-3,065 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$90.24 - $124.05 $276,585 - $380,213	3,065 New	3,065 $293,000

673

162M

2.58M

2.19M

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $10.2B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.